Annual SG&A
$734.00 K
-$116.00 K-13.65%
31 December 2023
Summary:
XTL Biopharmaceuticals annual selling, general & administrative expenses is currently $734.00 thousand, with the most recent change of -$116.00 thousand (-13.65%) on 31 December 2023. During the last 3 years, it has fallen by -$176.00 thousand (-19.34%). XTLB annual SG&A is now -86.85% below its all-time high of $5.58 million, reached on 31 December 2007.XTLB Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$169.00 K
-$25.00 K-12.89%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly selling, general & administrative expenses is currently $169.00 thousand, with the most recent change of -$25.00 thousand (-12.89%) on 31 March 2024. Over the past year, it has increased by +$24.00 thousand (+16.55%). XTLB quarterly SG&A is now -89.73% below its all-time high of $1.65 million, reached on 01 March 2009.XTLB Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$631.72 M
-$376.00 K-0.06%
31 March 2024
Summary:
XTL Biopharmaceuticals TTM selling, general & administrative expenses is currently -$631.72 million, with the most recent change of -$376.00 thousand (-0.06%) on 31 March 2024. Over the past year, it has dropped by -$632.48 million (-83330.57%). XTLB TTM SG&A is now -695.91% below its all-time high of $4.11 million, reached on 30 June 2013.XTLB TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.7% | +16.6% | -10000.0% |
| 3 y3 years | -19.3% | -17.2% | -10000.0% |
| 5 y5 years | -2.8% | -11.1% | -10000.0% |
XTLB Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -26.7% | at low | -39.6% | +16.6% | -103.8% | at low |
| 5 y | 5 years | -26.7% | at low | -63.3% | +16.6% | -313.7% | at low |
| alltime | all time | -86.8% | +130.2% | -89.7% | +103.3% | -695.9% | at low |
XTL Biopharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | $169.00 K(-12.9%) | $665.00 K(-9.4%) |
| Dec 2023 | $734.00 K(-13.6%) | $194.00 K(+33.8%) | $734.00 K(-3.3%) |
| Sept 2023 | - | $145.00 K(-7.6%) | $759.00 K(-6.9%) |
| June 2023 | - | $157.00 K(-34.0%) | $815.00 K(-3.6%) |
| Mar 2023 | - | $238.00 K(+8.7%) | $845.00 K(-0.6%) |
| Dec 2022 | $850.00 K(-15.1%) | $219.00 K(+9.0%) | $850.00 K(-6.7%) |
| Sept 2022 | - | $201.00 K(+7.5%) | $911.00 K(-0.3%) |
| June 2022 | - | $187.00 K(-23.0%) | $914.00 K(-10.7%) |
| Mar 2022 | - | $243.00 K(-13.2%) | $1.02 M(+2.3%) |
| Dec 2021 | $1.00 M(+10.0%) | $280.00 K(+37.3%) | $1.00 M(+3.6%) |
| Sept 2021 | - | $204.00 K(-31.3%) | $966.00 K(-20.9%) |
| June 2021 | - | $297.00 K(+35.0%) | $1.22 M(-11.8%) |
| Mar 2021 | - | $220.00 K(-10.2%) | $1.38 M(-2.4%) |
| Dec 2020 | $910.00 K(+12.8%) | $245.00 K(-46.6%) | $1.42 M(+0.6%) |
| Sept 2020 | - | $459.00 K(-0.2%) | $1.41 M(+23.6%) |
| June 2020 | - | $460.00 K(+81.1%) | $1.14 M(+30.9%) |
| Mar 2020 | - | $254.00 K(+7.6%) | $871.00 K(+7.9%) |
| Dec 2019 | $807.00 K(+6.9%) | $236.00 K(+24.2%) | $807.00 K(+3.1%) |
| Sept 2019 | - | $190.00 K(-0.5%) | $783.00 K(+1.2%) |
| June 2019 | - | $191.00 K(+0.5%) | $774.00 K(+2.1%) |
| Mar 2019 | - | $190.00 K(-10.4%) | $758.00 K(+0.4%) |
| Dec 2018 | $755.00 K(-37.2%) | $212.00 K(+17.1%) | $755.00 K(-9.4%) |
| Sept 2018 | - | $181.00 K(+3.4%) | $833.00 K(0.0%) |
| June 2018 | - | $175.00 K(-6.4%) | $833.00 K(-23.3%) |
| Mar 2018 | - | $187.00 K(-35.5%) | $1.09 M(-9.7%) |
| Dec 2017 | $1.20 M(-5.3%) | $290.00 K(+60.2%) | $1.20 M(-0.2%) |
| Sept 2017 | - | $181.00 K(-57.7%) | $1.21 M(-6.5%) |
| June 2017 | - | $428.00 K(+40.8%) | $1.29 M(+7.0%) |
| Mar 2017 | - | $304.00 K(+4.1%) | $1.21 M(-5.1%) |
| Dec 2016 | $1.27 M(-10.1%) | $292.00 K(+10.2%) | $1.27 M(-8.1%) |
| Sept 2016 | - | $265.00 K(-23.0%) | $1.38 M(+0.2%) |
| June 2016 | - | $344.00 K(-6.8%) | $1.38 M(-4.7%) |
| Mar 2016 | - | $369.00 K(-8.7%) | $1.45 M(+2.5%) |
| Dec 2015 | $1.41 M(-17.9%) | $404.00 K(+54.2%) | $1.41 M(-4.9%) |
| Sept 2015 | - | $262.00 K(-36.4%) | $1.48 M(-4.2%) |
| June 2015 | - | $412.00 K(+23.4%) | $1.55 M(+2.9%) |
| Mar 2015 | - | $334.00 K(-29.8%) | $1.51 M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | $1.72 M(+34.1%) | $476.00 K(+45.6%) | $1.72 M(-368.2%) |
| Sept 2014 | - | $327.00 K(-11.4%) | -$641.00 K(+30.8%) |
| June 2014 | - | $369.00 K(-32.5%) | -$490.00 K(-210.6%) |
| Mar 2014 | - | $547.00 K(-129.0%) | $443.00 K(-65.4%) |
| Dec 2013 | $1.28 M(-46.6%) | -$1.88 M(-494.1%) | $1.28 M(-63.2%) |
| Sept 2013 | - | $478.00 K(-63.3%) | $3.48 M(-15.3%) |
| June 2013 | - | $1.30 M(-6.1%) | $4.11 M(+20.9%) |
| Mar 2013 | - | $1.39 M(+340.0%) | $3.40 M(+41.8%) |
| Dec 2012 | $2.40 M(+133.4%) | $315.00 K(-71.6%) | $2.40 M(+2.0%) |
| Sept 2012 | - | $1.11 M(+87.6%) | $2.35 M(+57.5%) |
| June 2012 | - | $591.00 K(+53.9%) | $1.49 M(+30.9%) |
| Mar 2012 | - | $384.00 K(+42.8%) | $1.14 M(+8.9%) |
| Dec 2011 | $1.03 M(-15.9%) | $269.00 K(+7.6%) | $1.05 M(-0.5%) |
| Sept 2011 | - | $250.00 K(+5.0%) | $1.05 M(-4.2%) |
| June 2011 | - | $238.00 K(-18.2%) | $1.10 M(-6.7%) |
| Mar 2011 | - | $291.00 K(+6.2%) | $1.18 M(-3.6%) |
| Dec 2010 | $1.22 M(-150.3%) | $274.00 K(-7.4%) | $1.22 M(-129.0%) |
| Sept 2010 | - | $296.00 K(-6.6%) | -$4.21 M(-3.8%) |
| June 2010 | - | $317.00 K(-5.4%) | -$4.38 M(+25.7%) |
| Mar 2010 | - | $335.00 K(-106.5%) | -$3.48 M(+60.4%) |
| Dec 2009 | -$2.43 M(-161.7%) | -$5.16 M(-4067.7%) | -$2.17 M(-198.1%) |
| Sept 2009 | - | $130.00 K(-89.3%) | $2.21 M(-31.6%) |
| June 2009 | - | $1.21 M(-26.3%) | $3.23 M(-3.7%) |
| Mar 2009 | - | $1.65 M(-311.6%) | $3.36 M(+96.1%) |
| Dec 2008 | $3.94 M(-29.5%) | -$778.00 K(-167.5%) | $1.71 M(-31.2%) |
| Sept 2008 | - | $1.15 M(-13.8%) | $2.49 M(+86.2%) |
| June 2008 | - | $1.34 M(+6.0%) | $1.34 M(+6.0%) |
| Dec 2007 | $5.58 M(+0.1%) | - | - |
| June 2007 | - | $1.26 M(-0.3%) | $1.26 M(-0.3%) |
| Dec 2006 | $5.58 M(+2.2%) | - | - |
| June 2006 | - | $1.27 M(+58.3%) | $1.27 M(+58.3%) |
| Dec 2005 | $5.46 M(+32.0%) | - | - |
| June 2005 | - | $800.00 K(+14.6%) | $800.00 K(+14.6%) |
| Dec 2004 | $4.13 M(+33.1%) | - | - |
| June 2004 | - | $698.00 K | $698.00 K |
| Dec 2003 | $3.10 M(-14.7%) | - | - |
| Dec 2002 | $3.64 M(+21.2%) | - | - |
| Dec 2001 | $3.00 M | - | - |
FAQ
- What is XTL Biopharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual SG&A year-on-year change?
- What is XTL Biopharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly SG&A year-on-year change?
- What is XTL Biopharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals TTM SG&A year-on-year change?
What is XTL Biopharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of XTLB is $734.00 K
What is the all time high annual SG&A for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual selling, general & administrative expenses is $5.58 M
What is XTL Biopharmaceuticals annual SG&A year-on-year change?
Over the past year, XTLB annual selling, general & administrative expenses has changed by -$116.00 K (-13.65%)
What is XTL Biopharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of XTLB is $169.00 K
What is the all time high quarterly SG&A for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly selling, general & administrative expenses is $1.65 M
What is XTL Biopharmaceuticals quarterly SG&A year-on-year change?
Over the past year, XTLB quarterly selling, general & administrative expenses has changed by +$24.00 K (+16.55%)
What is XTL Biopharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of XTLB is -$631.72 M
What is the all time high TTM SG&A for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high TTM selling, general & administrative expenses is $4.11 M
What is XTL Biopharmaceuticals TTM SG&A year-on-year change?
Over the past year, XTLB TTM selling, general & administrative expenses has changed by -$632.48 M (-83330.57%)